KEMH at the forefront of hip replacement surgery

Monday 17 February 2025: Bermuda Hospitals Board (BHB) is part of a US Food and Drug Administration (FDA) clinical study to bring a new orthopaedic implant to the United States. The Polymotion Hip Resurfacing (PHR^TM) is a new hip replacement device that will be used in men and women under age 65 as a part of the clinical study. In time, Polymotion may join its predecessor, the Birmingham Hip Resurfacing (BHR^TM), as a globally available hip resurfacing device.

Orthopaedic surgeon Dr Ronan Treacy (pictured left) is a co-inventor of Polymotion. He also designed the Birmingham implant in the late 1990s. He’s been a regular visiting surgeon in Bermuda for over 25 years and has performed hundreds of Birmingham Hip Resurfacing procedures on local residents at King Edward VII Memorial Hospital (KEMH).

BHB Director of Orthopaedics Dr William Peckett has worked with Dr Treacy for over 20 years and has been trained to implant both the Birmingham and the Polymotion devices.

Dr Treacy and Dr Peckett did the first hip replacement surgeries using the Polymotion implant at KEMH in January as part of the Investigational Device Exemption (IDE) study for the FDA.

Dr Treacy said: “I believe we are the first overseas centre ever to have taken part in such a study. We are privileged to be in the company of fantastic centres such as NYU, New York; RUSH University Medical Center in Chicago and some of the biggest names in hip surgery in the world.”

“In total, the team performed the surgery on four patients. Each went home on the day of surgery. All are recovering well.”

Most patients who undergo hip replacement surgery at KEMH are discharged home the same day.

Dr Treacy said: “The patients actually prefer to go home and be in their own bed in their first night. The level of pain control isn’t really an issue. Patients are very mobile afterwards.”

“This is the trend in the United States. We haven’t quite caught up in the UK. In fact, we are far in advance here at the King Edward Hospital to regular practice in the UK.”

Although the Bermuda surgeries were the first in the US study, Dr Treacy has successfully implanted metal-on-polyethylene hip resurfacings (similar to the Polymotion) in Birmingham, UK, for the last 9 years. He has performed about 90 surgeries.

Worldwide, approximately 250 of these metal-on-polyethylene resurfacing devices have been implanted. The Polymotion is currently being used regularly in New Zealand on general release to treat various hip conditions. It is also going through the necessary regulatory processes in other global markets, including Australia and Canada.

Dr Peckett will perform most of the local clinical study cases. He said: “We are excited to be one of only ten centres that were chosen for this study. The other nine are all in the US.”

“Over 200 patients are expected to be enrolled in the study, which will run for at least 2 years. We would be expecting to enroll approximately 20 Bermudian patients in total over that time period.”

JointMedica, manufacturers of Polymotion, were on hand at the surgeries last week. President of the company, Dr. Sharat Kusuma, also an orthopaedic surgeon, said adding a polyethylene lining

to the socket of the metal ball and socket device differentiates it from its predecessor, the Birmingham. Over the past ten years, metal-on-metal hip replacement devices (like the Birmingham) have become less popular due to the metal-on-metal bearing surface. The Polymotion device incorporates several design features of Birmingham resurfacing but eliminates the metal-metal bearing surface.

Dr Treacy said: “Dr Peckett just did his 300^th outpatient joint replacement here over the last two years. This is an extraordinary achievement due in large part to the King Edward nursing staff, radiology staff, its anaesthetic staff, and a lot of pre-operative work.”

BHB Chief of Surgery Dr. Alicia Stovell-Washington said: “We are proud that JointMedica has included KEMH as a site for this FDA study; it reinforces that our surgical department has world-class staff and processes.”

We thank Drs Treacy and Peckett for spearheading this effort to improve the lives of our patients.

Bringing the Polymotion clinical study to Bermuda completely aligns with our BHB vision; To pursue excellence through improvement, to make Bermuda proud.”

For more information on the Polymotion device click here.

Pictured at the top, from left: Tim Band, Senior Director Market Development, JointMedica; Dr William Peckett, BHB Director of Orthopaedics; Dr Sharat Kusuma, President, JointMedica; Jason Osier and Warner Watkins, JointMedica distribution agents.